<DOC>
	<DOCNO>NCT02799888</DOCNO>
	<brief_summary>HLA-mismatched unrelated donor ( MMUD ) HLA-haploidentical donor ( Haplo Donor ) hematopoietic stem cell transplantation ( HSCT ) associate increase graft-versus-host-disease ( GVHD ) impair survival . The chemokine receptor 5 ( CCR5 ) antagonist maraviroc immunomodulatory property potentially beneficial GVHD control blockade lymphocyte chemotaxis without impair T-cell function . The aim study evaluate safety efficacy maraviroc combine standard graft-versus-host-disease prophylaxis patient hematologic malignancy allogeneic stem cell transplantation HLA-Unrelated HLA-Mismatched Related donor . Based result previously small sample study maraviroc combine cyclosporine/tacrolimus methotrexate prophylaxis GVHD , investigator plan perform clinical trail .</brief_summary>
	<brief_title>Maraviroc-Based GVHD Prophylaxis HLA-Unrelated HLA-Mismatched Related Transplantation</brief_title>
	<detailed_description />
	<mesh_term>Graft v Host Disease</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Maraviroc</mesh_term>
	<criteria>1 . Age 1265 year ( patient old 12.0 less 66.0 year old ) 2 . Patients acute leukemia , myelodysplastic syndrome lymphoma schedule undergo allogeneic stemcell transplantation HLAUnrelated HLAMismatched Related donor 3 . Renal function : estimate creatinine clearance great 40 mL/minute ( use CockcroftGault formula actual body weight ) 4 . Hepatic function : Baseline direct bilirubin , alanine aminotransferase ( ALT ) low three time upper limit normal 5 . Pulmonary disease : force vital capacity ( FVC ) force expiratory volume one second ( FEV1 ) &gt; 40 % predict 6 . Cardiac ejection fraction &gt; 40 % 7 . Signed informed consent 1 . Patients expect available followup institution least 100 day transplant 2 . Prior allogeneic transplant 3 . Karnofsky Performance Score &lt; 70 % 4 . Patients undergo standard GVHD prophylaxis cyclosporine/tacrolimus methotrexate 5 . Patients uncontrolled bacterial , viral fungal infection 6 . Patients receive investigational drug GVHD</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Graft-versus-host Disease</keyword>
	<keyword>Hematopoietic Stem Cell Transplantation</keyword>
	<keyword>Acute Leukemia</keyword>
	<keyword>Myelodysplastic syndrome</keyword>
	<keyword>Lymphoma</keyword>
</DOC>